BUSINESS J&J quarterly profit beats on demand for cancer drugs

BUSINESS

J&J quarterly profit beats on demand for cancer drugs

Reuters

20:20, April 17, 2018

Johnson & Johnson (JNJ.N) reported a better-than-expected first-quarter profit on Tuesday and raised its full-year sales forecast, helped by growing demand for its cancer drugs.

无标题1.png

The Johnson and Johnson logo is seen at an office building in Singapore January 17, 2018. (Photos: Reuters)

J&J’s pharmaceuticals sales rose 3.8 percent to $3.04 billion, driven by sales of its cancer drugs such as Darzalex, Imbruvica and Zytiga that rose 45 percent to $2.31 billion in the quarter.

无标题2.png

Johnson & Johnson products are displayed for sale in Solana Beach, California, U.S., July 17, 2017. 

J&J raised its full-year sales forecast to $81.0 billion to $81.8 billion from its previous forecast of $80.6 billion to $81.4 billion.

Excluding items, the company earned $2.06 per share. Analysts on average were expecting earnings of $2.02 per share, according to Thomson Reuters I/B/E/S.

Sales in the first quarter jumped to $20.01 billion from $17.77 billion a year earlier, beating analysts’ estimates of $19.46 billion.

Net earnings fell to $4.37 billion, or $1.60 per share, from $4.42 billion, or $1.61 per share, a year earlier.

Shares in the Dow-component were up 1.1 percent to $133.25 before the bell.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue